Titan Spine appoints Brian Burke as Chief Operating Officer

Titan Spine appoints Brian Burke as Chief Operating Officer

Titan Spine, a medical device surface technology company focused on developing innovative spinal interbody fusion implants, recently announced the appointment of Brian Burke as Chief Operating Officer (COO).

In his role, Mr Burke will have broad cross-functional responsibility for the company’s main business functions of sales, marketing, operations, hospital contracting, research and development, human resources, and legal, all to further support the growth of the company and adoption of its nanoLOCK® surface technology.

nanoLOCK® is the company’s next-generation surface technology featuring enhanced micro and nano-scaled architecture, proven to significantly improve the osteogenic response it creates.1

Peter Ullrich, Chief Executive Officer of Titan Spine, commented, “As we continue to focus on growth, we identified a need to bring on additional executive talent to the Titan Spine team. Brian has extensive experience driving effective and dynamic functional leadership, brings a wealth of experience in the medtech industry working with both privately and publicly held companies, and has demonstrated a proven track record of implementing operational efficiency. We welcome Brian and believe he will be instrumental in expanding Titan’s strategic positioning in the marketplace.”

Prior to joining Titan Spine, Mr. Burke served as General Manager for Zimmer Biomet Dental in North America where he successfully led the integration of commercial sales and marketing in the United States and Canada following the $13.4B acquisition of Biomet by Zimmer in 2015, which created the second-largest company in the dental implant and oral reconstructive surgery market. He was responsible for leading all North American sales channels that encompassed direct sales, inside sales, and specialty sales. Before Zimmer Biomet, Brian was Group Director of Latin America and Asia for Biomet 3i, where he managed all sales and marketing activities while also managing regulatory compliance and in-country manufacturing in specific global areas.

Reference: 1 Olivares-Navarrete, R., Hyzy S.L., Gittens, R.A., Berg, M.E., Schneider, J.M., Hotchkiss, K., Schwartz, Z., Boyan, B. D. Osteoblast lineage cells can discriminate microscale topographic features on titanium-aluminum-vanadium surfaces. Ann Biomed Eng. 2014 Dec; 42 (12): 2551-61.

More more information, visit: http://www.titanspine.com/

Categories: COMPANY NEWS
Tags: Titan Spine

Write a Comment

Your e-mail address will not be published.
Required fields are marked*